1167 — Jacobio Pharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00
- HK$1.34bn
- HK$334.33m
- CNY63.52m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 486 | 153 | 95.7 | 63.5 |
Cost of Revenue | |||||
Gross Profit | — | 442 | 12.8 | 12.6 | 3.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 194 | 307 | 472 | 490 | 461 |
Operating Profit | -194 | 179 | -319 | -394 | -398 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -426 | -1,514 | -301 | -372 | -359 |
Provision for Income Taxes | |||||
Net Income After Taxes | -426 | -1,514 | -301 | -372 | -359 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -425 | -1,514 | -301 | -372 | -359 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -425 | -1,514 | -301 | -372 | -359 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.559 | -1.96 | -0.403 | -0.495 | -0.465 |